Stand aside — setup invalidated
Setup score 87, but distribution days reach 5 or more — stand aside until the condition resets.
Simple research view
MRNA · Moderna, Inc.
$136.62 +0.74% Sep 10 close
Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.
$MRNA
Moderna, Inc.Moderna, Inc. is a large-cap Biotechnology company in the Health Technology sector with a market cap of $55B.
Verdict · setup score 87/100 · data Sep 10 close · 1 session old
Stand aside — setup invalidated
Setup score 87, but distribution days reach 5 or more — stand aside until the condition resets.
Earnings
Normal technical setup
No sourced report date
Event risk is not modelled for this symbol
Deterministic evidence
MRNA+0.74%
Sector proxy · XLV-0.55%
Broad market · SPY-0.60%
Session internals Strong momentum
Rule: closed up, at or above the open, in the top third of the day's range. Judged on internals, not on the size of the move.
Vs prior close+0.74%
From the open+1.56%
Range position92%
GapNo gap
QQQ confirmationDiverging (-1.06%)
SMH confirmationDiverging (-2.44%)
Short-term conviction -1 points.
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.
- QQQ, SMH moved against the stock — no index confirmation.
Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.
More stats
52W Low
$22.28
Tight Wks
0
Base
B5
SMA 200
$56.53
RS Line vs High
-20.5%
RS Line Slope
+120.3% ▲
Group Rank
#15/58
ADR%
9.8%
ATR(14)
$12.88 (9.4%)
Vol Pace (live)
N/A
U/D Vol
1.76
A/D Days
6A / 5D
A/D Rating
B
VDU Bars
0/10 d
Power Trend
16d
MRNA Chart
Interactive price, volume, RS, RSI, and MACD charts are available after sign in.
Technical Analysis Report Card
$MRNA · $136.62 · as of 2026-09-10 · multi-factor read
98
/ 100
Reference read from price & volume only — the verdict at the top of the page decides the action.
Trend · Daily / Weekly / Monthly
Daily
▲ Uptrend
Weekly
▲ Uptrend
Monthly
▲ Uptrend
Moving Averages
50-day$89.61 ↑
100-day$70.70 ↑
200-day$56.53 ↑
Bullish (50 > 200)
RSI (14)
Reading58.5 · Bullish
Bullish momentum — comfortably in buyer territory.
MACD (12/26/9)
StateWeakening
Histogram-2.536
Weakening — MACD slipped below its signal line. Histogram contracting.
Bollinger Bands (20,2)
%B / Width55% · 108.2%
Mid-band — no directional band edge in play.
Volume · Buyer vs Seller
Up/Down vol1.76 · Accumulation
Rel volume0.45×
Accumulation — volume is concentrated on up days; buyers dominate. Recent volume is easing versus its baseline.
Support & Resistance
R · $156.42swing level
R · $176.6652-week high
Price · $136.62now
S · $52.66swing level
S · $48.09swing level
S · $47.14swing level
Fibonacci · Uptrend swing
23.6%$145.28
38.2%$125.86
50.0%$110.17
61.8%$94.48
78.6%$72.14
Retracement support zones measured from the recent swing low up to the high.
The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for MRNA — plus the full 500+ symbol scanner and Ask-the-Legends chat.
Start your 7-day free trial →
Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishVolume accumulation
Want this read in a legend's voice?
Ask a Legend about MRNA
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts
6 methodology checks
Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
Council consensus:
5 of 6 legends are Watching — building, not yet a confirmed buy.
Watch
Minervini C
Trend-template read: 7/10 pass; wait for the soft misses to improve.
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $136.62, MA150 $63.90, MA200 $56.53
1.2 150-day MA > 200-day MAMA150 $63.90 vs MA200 $56.53
Failing evidence
2. Quarterly EPS growth ≥ 25%From SEPA scan
2. ROE ≥ 17%From SEPA scan
Avoid
O'Neil D
CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
Passing evidence
L: RS rank ≥ 80 (IBD leadership)RS rank 99
Failing evidence
C: Quarterly EPS acceleration ≥ 25%Data unavailable
A: Annual earnings & revenue qualityRev -39.9%
Watch
Weinstein C
Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.
Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $136.62 vs MA200 $56.53
Failing evidence
Volume expansion above averageVolume ratio 0.45x
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
Watch
Livermore B
Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$136.62
Relative strengthRS 99
Failing evidence
Volume vs average0.45x
Pivotal point cleared on expanding volumeNot confirmed
Watch
Darvas B
Box-theory read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$136.62
Relative strengthRS 99
Failing evidence
Volume vs average0.45x
Box top broken on heavy volumeNot confirmed
Watch
Wyckoff B
Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$136.62
Relative strengthRS 99
Failing evidence
Volume vs average0.45x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
Base & Breakout
Breakout follow-through
No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?
RS Line vs SPY
52-week relative strength · blue = RS line · dashed = MA50 · dot = NH
▲ Rising
Accumulation / Distribution
last 65 sessions · green = acc on high vol · red = dist on high vol
Net +6
Fundamentals & leadership quality — Minervini’s published criteria · 3/7 met
C
3/7 criteria
Separate score from the Minervini Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ
—
Revenue growth ≥20% YoY
-40%
Gross margin ≥30%
—
ROE ≥17%
—
RS rating ≥80 (leadership)
99
Stage 2 uptrend (Weinstein)
Stage 2
Within 25% of 52W high
-22.7%
Method Playbook
Trade it like Livermore
EXACT LEVELS · PRO
Livermore B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro levelPublished-method rule: Treat the resistance break as a pivotal point only while the primary trend and relative strength remain aligned.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro levelPublished-method rule: Wait for price and volume to confirm the pivotal-point break; anticipation below the line is not confirmation.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro levelPublished-method rule: Place the initial stop below the pivotal line or the reaction low that would prove the breakout false.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-basedPublished-method rule: Raise protection beneath successive higher reaction lows as the trend advances; never move a protective line farther away.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro levelPublished-method rule: Exit when price fails the pivotal line, breaks the latest meaningful reaction low, or shows abnormal reversal action.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →
Pattern Analysis
87
setup score
RS Score
99
Trend template
8/8 ✓
Why This Setup?
Trend Only · schematic
Gatekeeper 8/8 | Strong trend (8/8) | Top RS (99) | Volume drying up (bullish) | Accumulation (1.8× up/dn vol) | Power Trend | Stage 2
The Universal Edge Check · context only
What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.
2/7
universals met
- Risk is defined — not met No stop — undefined risk
- Asymmetric reward — partly met No target set
- Clear of earnings — partly met Report date unknown
- Not chasing (in range) — partly met Pivot distance unknown
- Volume confirms — partly met 0.5× average — light
- A relative-strength leader — met RS rank 99
- In a confirmed uptrend — met Stage 2 · Trend template 8/8
Minervini Trend Template
8/8 ✓Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.
Price above SMA 150 & 200
$136.62 vs SMA150 $63.90 / SMA200 $56.53
SMA 150 above SMA 200
SMA150 $63.90 vs SMA200 $56.53
SMA 200 trending up
Slope +10.42 over 20 days
SMA 50 above SMA 150 & 200
SMA50 $89.61
Price above SMA 50
$136.62 vs SMA50 $89.61
30%+ above 52-week low
+513.2% from $22.28
Within 25% of 52-week high
-22.7% from $176.66
RS score above 70
RS 99
Fundamentals
52W Range
74%
Mkt Cap SEC
54.5B
Rev YoY
-40%
EPS TTM
$-7.26
Float
399M
Company
Company profile
Moderna, Inc.
Weekly Context
Multi-timeframe signals from weekly barsW. Trend
8/8
W. RS
100
W. Support
$43.68
W. Resist
$176.66
Weekly Structure
Trend
Neutral
Tight Weeks
0
Confirmation
Neutral
Scan History
20× streakSep 11
Trend Only
✓ Gate
87
Sep 10
Trend Only
✓ Gate
87
0.0%
Sep 09
Trend Only
✓ Gate
88
+0.7%
Get the full picture on MRNA
Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.
Start 7-Day Free Trial